<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094336</url>
  </required_header>
  <id_info>
    <org_study_id>20210023</org_study_id>
    <nct_id>NCT05094336</nct_id>
  </id_info>
  <brief_title>AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors</brief_title>
  <acronym>MTAP</acronym>
  <official_title>A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability,&#xD;
      and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG&#xD;
      193 alone and in combination with docetaxel in adult participants with metastatic or locally&#xD;
      advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.&#xD;
&#xD;
      The primary objective of Part 3 of this study is to evaluate the objective response rate&#xD;
      (ORR) of AMG 193 in adult participants with metastatic or locally advanced MTAP-null&#xD;
      non-small cell lung cancer (NSCLC), after prior treatment with chemotherapy and/or a&#xD;
      programmed death-1/ligand 1 (PD-1/L1) inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">November 13, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs.&#xD;
Serious AEs (SAEs) are defined as any event that meets at least 1 of the following serious criteria:&#xD;
Results in death (fatal)&#xD;
Requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent or significant disability/incapacity&#xD;
Is a congenital anomaly/birth defect&#xD;
Other medically important serious event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Maximal Plasma Concentration (Cmax) of AMG 193</measure>
    <time_frame>Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Part 1 Cycle = 28 days, Part 2 Cycle =21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Time to Achieve Maximal Plasma Concentration (Tmax) of AMG 193</measure>
    <time_frame>Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Part 1 Cycle = 28 days, Part 2 Cycle =21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Area Under the Plasma Concentration Versus Time Curve (AUC) of AMG 193</measure>
    <time_frame>Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Part 1 Cycle = 28 days, Part 2 Cycle =21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Only: Maximal Plasma Concentration (Cmax) of Docetaxel</measure>
    <time_frame>Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Cycle =21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Only: Time to Achieve Maximal Plasma Concentration (Tmax) of Docetaxel</measure>
    <time_frame>Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Cycle =21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Only: Area Under the Plasma Concentration Versus Time Curve (AUC) of Docetaxel</measure>
    <time_frame>Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Cycle =21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2 and 3: Disease Control Rate (DCR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2 and 3: Duration of Response (DoR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2 and 3: Time to Response (TTR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2 and 3: Duration of Stable Disease (SD)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2 and 3: Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2 and 3: Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 Only: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs.&#xD;
Serious AEs (SAEs) are defined as any event that meets at least 1 of the following serious criteria:&#xD;
Results in death (fatal)&#xD;
Requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent or significant disability/incapacity&#xD;
Is a congenital anomaly/birth defect&#xD;
Other medically important serious event</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Advanced MTAP-null Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1a and 1b, Phase 1: AMG 193 Monotherapy Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MTAP-null solid tumors will receive escalating doses of AMG 193 to estimate the MTD and/or the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1c, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:&#xD;
MTAP-null squamous NSCLC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2a, Phase 1: AMG 193 Dose Exploration + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MTAP-null NSCLC will receive escalating doses of AMG 193 + a fixed dose of docetaxel to estimate the MTD/RP2D of the combination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2b, Phase 1: AMG 193 + Docetaxel Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MTAP-null NSCLC will receive the identified MTD/RP2D of AMG 193 + docetaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: AMG 193 Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MTAP-null NSCLC will receive AMG 193.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1d, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:&#xD;
MTAP-null adenocarcinoma NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1e, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:&#xD;
MTAP-null cholangiocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1f, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:&#xD;
MTAP-null head and neck squamous cell carcinoma (HNSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1g, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:&#xD;
MTAP-null pancreatic adenocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1h, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:&#xD;
MTAP-null solid tumor other than squamous or adenocarcinoma NSCLC, cholangiocarcinoma, HNSCC, pancreatic adenocarcinoma, primary brain tumor, and lymphoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 193</intervention_name>
    <description>AMG 193: Orally via tablet</description>
    <arm_group_label>Part 1a and 1b, Phase 1: AMG 193 Monotherapy Dose Exploration</arm_group_label>
    <arm_group_label>Part 1c, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_label>Part 1d, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_label>Part 1e, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_label>Part 1f, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_label>Part 1g, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_label>Part 1h, Phase 1: AMG 193 Monotherapy Dose Expansion</arm_group_label>
    <arm_group_label>Part 2a, Phase 1: AMG 193 Dose Exploration + Docetaxel</arm_group_label>
    <arm_group_label>Part 2b, Phase 1: AMG 193 + Docetaxel Dose Expansion</arm_group_label>
    <arm_group_label>Part 3: AMG 193 Phase 2</arm_group_label>
    <other_name>MTA Cooperative PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel: Intravenous infusion</description>
    <arm_group_label>Part 2a, Phase 1: AMG 193 Dose Exploration + Docetaxel</arm_group_label>
    <arm_group_label>Part 2b, Phase 1: AMG 193 + Docetaxel Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has provided informed consent/assent before initiation of any study&#xD;
             specific activities/procedures.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Evidence of homozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) (null)&#xD;
             and/or methylthioadenosine phosphorylase (MTAP) (null) or lost MTAP expression in the&#xD;
             tumor tissue.&#xD;
&#xD;
          -  Histologically confirmed metastatic or locally advanced solid tumor not amenable to&#xD;
             curative treatment with surgery and/or radiation.&#xD;
&#xD;
          -  Able to swallow and retain orally (PO) administered study treatment and willing to&#xD;
             record daily adherence to investigational product.&#xD;
&#xD;
          -  Disease measurable as defined by Response Evaluation Criteria in Solid Tumors Version&#xD;
             1.1 (RECIST v1.1).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          -  Adequate hematopoietic function per local laboratory.&#xD;
&#xD;
          -  Adequate renal function per local laboratory.&#xD;
&#xD;
          -  Adequate glucose control per local laboratory (Part 1 only).&#xD;
&#xD;
          -  Adequate liver function per local laboratory.&#xD;
&#xD;
          -  Adequate coagulation parameters.&#xD;
&#xD;
          -  Adequate pulmonary function.&#xD;
&#xD;
          -  Adequate cardiac function.&#xD;
&#xD;
          -  Minimum life expectancy of 12 weeks as per investigator judgement.&#xD;
&#xD;
          -  Tumor tissue must be available.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Spinal cord compression or active brain metastases or leptomeningeal disease from&#xD;
             non-brain tumors.&#xD;
&#xD;
          -  Presence of primary brain cancer.&#xD;
&#xD;
          -  Presence of hematological malignancy or lymphoma.&#xD;
&#xD;
          -  History of other malignancy within the past 2 years.&#xD;
&#xD;
          -  Evidence of lung disease.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  History of arterial thrombosis.&#xD;
&#xD;
          -  Myocardial infarction and/or symptomatic congestive heart failure, unstable angina, or&#xD;
             cardiac arrhythmia.&#xD;
&#xD;
          -  Gastrointestinal tract disease.&#xD;
&#xD;
          -  History of solid organ transplant.&#xD;
&#xD;
          -  Diagnosis of Congenital Short QT Syndrome.&#xD;
&#xD;
          -  Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a&#xD;
             protein arginine methyltransferase 5 (PRMT5) inhibitor.&#xD;
&#xD;
          -  Prior irradiation to greater than 25% of the bone marrow.&#xD;
&#xD;
          -  Unresolved toxicity from prior anti-cancer therapy.&#xD;
&#xD;
          -  Currently receiving treatment in another investigational device or drug study.&#xD;
&#xD;
          -  Known positive test for Human Immunodeficiency Virus.&#xD;
&#xD;
          -  Evidence of hepatitis B or C infection.&#xD;
&#xD;
          -  Female participants of childbearing potential with a positive pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic MTAP-null solid tumors</keyword>
  <keyword>Advanced MTAP-null solid tumors</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Adenocarcinoma NSCLC</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Head and neck squamous cell carcinoma</keyword>
  <keyword>Pancreatic adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

